• Psoriasis

Enstilar Generic Name & Formulations

General Description

Calcipotriene (as hydrate) 0.005% + betamethasone dipropionate 0.064%; foam.

Pharmacological Class

Vit. D3 derivative + topical steroid.

How Supplied

Foam—60g, 2x60g


Enstilar Indications


Plaque psoriasis.

Enstilar Dosage and Administration

Adults and Children

<12yrs: not established. ≥12yrs: apply to affected areas once daily for up to 4 weeks; max 60g every 4 days. Discontinue when control is achieved. Do not occlude.

Enstilar Contraindications

Not Applicable

Enstilar Boxed Warnings

Not Applicable

Enstilar Warnings/Precautions


Avoid use near eyes, on face, groin, or axillae, or if atrophy is present at treatment site. Discontinue if hypercalcemia or hypercalciuria develop; may resume once calcium metabolism has normalized. Discontinue or reduce dose or potency if HPA axis suppression, Cushing's syndrome, or hyperglycemia occurs. Increased risk of posterior subcapsular cataracts and glaucoma; monitor for visual symptoms. Flammable. Allergic contact dermatitis. Pregnancy. Nursing mothers.

Enstilar Pharmacokinetics

See Literature

Enstilar Interactions


Systemic absorption potentiated by other corticosteroids.

Enstilar Adverse Reactions

Adverse Reactions

Application site irritation and pruritus, folliculitis, skin hypopigmentation, hypercalcemia, urticaria, psoriasis exacerbation.

Enstilar Clinical Trials

See Literature

Enstilar Note

Not Applicable

Enstilar Patient Counseling

See Literature